Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Moberg Pharma AB | 162,071 | net | 05 Jun 2025 | tx 15+229,218−67,147 |
| Saniona AB (publ) | 133,117 | net | 23 Jan 2024 | tx 7+133,117 |
| OncoZenge AB | 9,757 | net | 08 Mar 2021 | tx 1+9,757 |
3 purchases reported after at least 12 months of silence — most recent on 30 Aug 2023.
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 05 Jun 2025 | GRANT_AWARD | Moberg Pharma AB | 35,851 | 8.97 SEK | |
| 25 Jun 2024 | GRANT_AWARD | Moberg Pharma AB | 23,075 | 29.21 SEK | |
| 25 Jun 2024 | SALE | Moberg Pharma AB | 13,153 | 29.09 SEK | |
| 23 Jan 2024 | OTHER | Saniona AB (publ) | 37,020 | 0.00 SEK | deriv |
| 23 Jan 2024 | PURCHASE | Saniona AB (publ) | 2,468 | 4.12 SEK | |
| 04 Sept 2023 | PURCHASE | Moberg Pharma AB | 3,536 | 5.75 SEK | |
| 30 Aug 2023 | PURCHASE | Moberg Pharma AB | 13,118 | 5.75 SEK | first after silence |
| 19 May 2022 | PURCHASE | Moberg Pharma AB | 43,479 | 2.30 SEK | first after silence |
| 17 Mar 2021 | PURCHASE | Saniona AB (publ) | 4,629 | 21.58 SEK | |
| 08 Mar 2021 | PURCHASE | OncoZenge AB | 9,757 | 10.25 SEK | |
| 22 Dec 2020 | PURCHASE | Moberg Pharma AB | 16,326 | 6.47 SEK | first after silence |
| 26 Oct 2020 | GRANT_AWARD | Saniona AB (publ) | 77,000 | 0.00 SEK | deriv |
| 22 Nov 2019 | OTHER | Moberg Pharma AB | 13,994 | 46.50 SEK | |
| 15 Sept 2019 | GRANT_AWARD | Saniona AB (publ) | 4,000 | 0.00 SEK | deriv |
| 28 Jun 2019 | PURCHASE | Moberg Pharma AB | 40,000 | 42.97 SEK | |
| 28 Jun 2019 | SALE | Moberg Pharma AB | 40,000 | 66.67 SEK | |
| 26 Jun 2019 | PURCHASE | Moberg Pharma AB | 1,994 | 65.20 SEK | |
| 25 Jun 2019 | SALE | Moberg Pharma AB | 1,994 | 65.30 SEK | |
| 20 May 2019 | GRANT_AWARD | Moberg Pharma AB | 1,994 | 66.80 SEK | |
| 01 Jul 2018 | PURCHASE | Saniona AB (publ) | 4,000 | 0.00 SEK | |
| 21 Dec 2017 | SALE | Moberg Pharma AB | 12,000 | 28.20 SEK |